Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.38 |
| ▸ | CIT | O14578 | 1/20 | 0.34 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 6/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.33 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.33 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.33 |
| ▸ | ECE1 | P42892 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | FCER2 | P06734 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16359592 | 0.98 | ACE (0.39) | ACECITERAP2ERAP1LNPEP | |
| SCHEMBL31020882 | 0.90 | ECE1 (0.36) | RENERAP2ERAP1LNPEPECE1 | |
| SCHEMBL15011306 | 0.88 | ACE (0.42) | ACE | |
| SCHEMBL30874984 | 0.88 | ACE (0.42) | ACE | |
| SCHEMBL15011307 | 0.88 | ACE (0.42) | ACE | |
| SCHEMBL29615610 | 0.88 | CTSD (0.37) | LNPEPECE1ALDH1A1 | |
| SCHEMBL31433276 | 0.87 | ACE (0.39) | ACE | |
| SCHEMBL29384685 | 0.87 | ECE1 (0.37) | ACERENERAP2ERAP1LNPEP | |
| SCHEMBL29517172 | 0.87 | ERAP2 (0.35) | ACERENERAP2ERAP1LNPEP | |
| SCHEMBL30918507 | 0.87 | MAGI3 (0.37) | ACEECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197815-A1 | METHODS AND COMPOSITIONS FOR IMPROVING VISUAL FUNCTION IN OCULAR DISEASES AND DISORDERS | ONL THERAPEUTICS, INC. | 2024-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197815-A1 | METHODS AND COMPOSITIONS FOR IMPROVING VISUAL FUNCTION IN OCULAR DISEASES AND DISORDERS | PDE6C, UACA, EYA3 | ACE 1661/4885CIT 3095/4885PLG 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.